UroGen Pharma Profit Margin

UroGen Pharma (URGN) currently reports a profit margin of -51.73% as of June 2026. That compares with -164.44% in the prior-year period — up 68.5% year over year. That is below the Healthcare sector average of 13.39%. Use the charts on this page to explore UroGen Pharma's profit margin history and peer comparisons.

UroGen Pharma's profit margin increased from -164.44% to -51.73% — a 68.5% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

UroGen Pharma's profit margin of -51.73% is lower than the Healthcare sector average of 13.39%. That is roughly 486.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but UroGen Pharma's current -51.73% should be judged against Healthcare norms (sector average: 13.39%) and against URGN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -51.73%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.39%. From there, open related valuation or income-statement pages for UroGen Pharma, and consider following URGN for alerts when major investors trade the stock.